Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19004094 | 0.78 | MAPT (0.35) | LMNAALDH1A1MAPT | |
| SCHEMBL11185156 | 0.75 | LMNA (0.34) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL30549680 | 0.73 | ALDH1A1 (0.38) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL3177257 | 0.73 | ALDH1A1 (0.38) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL245602 | 0.71 | ABCB11 (0.44) | LMNAKMT2ADGAT1 | |
| SCHEMBL249487 | 0.71 | CNR2 (0.46) | LMNAKMT2ADGAT1 | |
| SCHEMBL15375598 | 0.70 | ALDH1A1 (0.40) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL19185845 | 0.70 | LMNA (0.36) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL1000276 | 0.70 | ALDH1A1 (0.40) | LMNAKMT2AALDH1A1MAPTGAA | |
| SCHEMBL25886400 | 0.70 | LMNA (0.36) | LMNAKMT2AALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | LMNA 2833/4885KMT2A 828/4885DGAT1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.